Elucidating the use of enoxaparin in non-ST-elevation acute coronary syndromes (NSTE-ACS)

The guidelines The new joint guidelines from the American Heart Association (AHA) and the American College of Cardiology (ACC) for non-ST-elevation acute coronary syndromes (NSTE-ACS) represent the culmination of a massive undertaking to synthesise a large body of evidence, and the guideline writing committee is to be applauded for their efforts in preparing these guidelines.1 2 As is the current standard, the online version of these guidelines was published ahead of print, and review of the electronic publication ahead of print revealed that the handling of enoxaparin was problematic.1 The problem concerned the discussion of giving an initial 30 mg intravenous loading dose of enoxaparin prior to administering 1 mg/kg of enoxaparin subcutaneously every 12 h (q12h) when enoxaparin is selected as the anticoagulant. The electronic version published ahead of the print version simply stated "An initial intravenous loading dose is 30 mg." (ref.
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Clinical trials (epidemiology), Editor's choice, Drugs: cardiovascular system, Stroke, Ischaemic heart disease Perspective Source Type: research